Plné znění - 80/2017 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2017 - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

80/2017 Sb. m. s.

Sdělení

INFORMACE

80

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Xx. m. x. a č. 46/2008 Xx. m. x.

 

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 28. listopadu 2016 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx znění Xxxxxxx X (Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx xxx 2017 - Mezinárodní xxxxxxxx) Mezinárodní úmluvy xxxxx xxxxxxx ve xxxxxx¹⁾.

X xxxxx zněním Xxxxxxx X vyslovil xxxxxxx Xxxxxxxxx České xxxxxxxxx a xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Xxxxxxx I Xxxxxx xxxxxxxxxx.

Xxxx znění Xxxxxxx X xxxxxxxxx x xxxxxxxx x souladu x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2017 x xxx Xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxxx xxx 30. xxxxx 2017.

Dnem xxxxxx xxxxxx znění Xxxxxxx X v xxxxxxxx xxxxxxxx xxxxxx znění Xxxxxxx X xxxxxx xx 1. ledna 2016, vyhlášené pod č. 26/2017 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx českého xxxxxx xx xxxxxxxxx xxxxxxxx.

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX PRO XXX 2017

XXXXXXXXXXX STANDARD

Oficiální xxxx Xxxxxxx xxxx xxxxxxxxx WADA x xxxx publikován x xxxxxxxxxx x xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx konfliktů xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxx verze.

Tento Xxxxxx bude platný xx 1. xxxxx 2017 

XXXXXX XXXXXXXXXX XXXXX X METOD XXXXXXX XXX ROK 2017

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. ledna 2017

Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx skupin X1, X2, S4.4, S4.5 x X6(x) x Xxxxxxxxxx metod M1, X2 x M3.

LÁTKY X METODY XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

ZAKÁZANÉ LÁTKY

S0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxxx xxxxxx látka, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx aktuálně xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx zdravotnickým regulačním xxxxxx (např. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx stadiu xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx použití), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX LÁTKY

Anabolické látky xxxx zakázány.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* AAS, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-hydroxy-2α,17α-dimethyl-5α-androstan-3-on);

methyldienolon (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9,11-trien-3-on);

miboleron;

norboleton;

norethandrolon;

norklostebol;

oxabolon;

oxandrolon;

oxymesteron;

oxymetolon;

prostanozol (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-hydroxyestr-4,9,11-trien-3-on);

a xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými biologickými xxxxxx.

x. Xxxxxxxxx** AAS, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (androst-4-en-3,17-dion);

boldenon;

boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxxxx-3xx); 

xxxxxxxxx (19-xxxxxxxxxxxxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (dehydroepiandrosteron, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x jejich xxxxxxxxxx a xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; selektivní modulátory xxxxxxxxxxxxx receptorů (SARM, xxxx. xxxxxxx x xxxxxxx); tibolon; zeranol x xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" se xxxxxxxx k xxxxx, xxxxxx tělo xxxxxxxx xxxxxxxxx neprodukuje. ** "xxxxxxxxx " se xxxxxxxx x xxxxx, xxxxxx xxxx normálně xxxxxxxxx xxxxxxxxx.

X2. PEPTIDOVÉ HORMONY, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx xxxxx a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Agonisté xxxxxxxxxxxxxxxxx xxxxxxxxx:

1.1 Xxxxx xxxxxxxxxxx xxxxxxxxxxx (XXX) xxxxxx xxxx.

xxxxxxxxxxxx (xXXX);

xxxxxxxxxxxxx (XXX);

XXX-Xx;

XXX-xxxxxxxxxxx xxxxxxx (XXX), xxxx. XXXX 530 x xxxxxxxxxxx;

xxxxxxxxxx XXXX, xxxx. K-11706;

methoxypolyethylenglykol-epoetin xxxx (XXXX);

xxxxxxxxxx transformujícího xxxxxxxxx xxxxxxx beta (TGF-beta), xxxx. sotatercept, xxxxxxxxxxxx;

1.2 Xxxxxxxx xxxxxxxxxxxxxxxxxx XXX xxxxxxxxx, např.

ARA-290;

asialo EPO;

karbamylovaný XXX;

2. Xxxxxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx, xxxxxxxxxx x roxadustat (XX-4592); x aktivátory XXX, xxxx. argon a xxxxx.

3. Choriogonadotropin (XX) x xxxxxxxxxxxx xxxxxx (XX) x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxx, gonadorelin a xxxxxxxxxxx, u xxxx.

4. Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx.

5. Xxxxxxx xxxxxx (XX) x xxxx xxxxxxxxxx xxxxxxx včetně: xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. XXX-1295, xxxxxxxxxxx a xxxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxxxx a xxxxxxx xxxxxxxx, např. xxxxxxxxxxx x ipamorelinu; uvolňujících xxxxxxx xxxxxxxxx xxxxxxx (XXXX), např. xxxxxxxxxxxxx, XXXX-6, hexarelinu x xxxxxxxxxxxx (XXXX- 2).

Kromě xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx:

Xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx); xxxxxxxxxxxx xxxxxxx xxxxxx (XXX); xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1) x xxxx xxxxxxx; xxxxxxxxxx růstové xxxxxxx (XXX); růstový faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX); xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (VEGF), xxxxxx jako xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx a xxxxxx, xxxxxx xxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx typy xxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx beta2- agonisté, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx pouze xx xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: maximálně 1600 xxxxxxxxxx xx 24 xxxxx, nepřekročit 800 xxxxxxxxxx xx každých 12 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx dodaná xxxxx 54 mikrogramů xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x xxxx x koncentraci vyšší xxx 1000 ng/ml x přítomnost formoterolu x xxxx x xxxxxxxxxxx xxxxx než 40 xx/xx nebude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx laboratorní xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx výsledek xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxx (v xxxxxxxx) xxxxx, než xxxx xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx modulátory:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-oxo);

exemestan;

formestan;

letrozol;

testolacton,

ale xx x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

Xxxxxxxxxx; fulvestrant x xxxxxxxx, ale xx s omezením xxxxx xx xx.

4. Xxxxx modifikující xxxxxx(x) xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx

x xxxxxxxx xxxxx xx xx.

5. Xxxxxxxxxxx modulátory:

5.1 Xxxxxxxxxx XXX-xxxxxxxxxx proteinkinázy (XXXX), xxxx. XXXXX; x Xxxxxxxx Receptoru xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), např. XX 1516;

5.2 Insuliny x mimetika xxxxxxxx;

5.3 Xxxxxxxxx;

5.4 Xxxxxxxxxxxx.

X5. DIURETIKA X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx x maskovací xxxxx jsou xxxxxxxx, xxxxxx xxxx další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx biologickými xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx a xxxxxxxxx), xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.

• Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx a xxxxxxx (xxxx. xxxxxxxxx), xxx xx x xxxxxxxx xxxxx na xx.

X xxxxxxxx:

• xxxxxxxxxxxx, xxxxxxxxx a xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x xxxxxxxxxxxx)

• Xxxxxxxxx podání xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx limitem (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, metylefedrin x xxxxxxxxxxxxx) xx Vzorku Xxxxxxxxx xxxxxxxx xxxx

xxxxxxxx Xxx Xxxxxxx ve xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Xxxxxxxxx laboratorní xxxxx, xxxxx Xxxxxxxxx xxxx schválenou Terapeutickou xxxxxxx (XX) xx xxxx xxxxx xxxxx x té, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx krvinek x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx systému.

2. Umělé xxxxxxxxx xxxxxxxx, xxxxxxx xxxx dodávky xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx x xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx ne s xxxxxxxx xxxxx xx xx. Inhalační xxxxxxxxxxxx xxxxxxxx xxxxxxxx není.

3. Xxxxxxxxx forma xxxxxxxxxxxxxxx xxxxxxxxxx x krví xxxx s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx nebo xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, za účelem xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx odebraných xxx Xxxxxxxxx kontrole. Xx zahrnuje záměnu x/xxxx úpravu (např. xxxxxxxxxx) xxxx, ale xx s xxxxxxxx xxxxx xx ně.

2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxxx xxxxxx xxxxxxxxx přijatých x xxxxxxx xxxxxxxxxxxx xxxxxxx, chirurgických xxxxxxx xxxx xxxxxxxxxx vyšetřovacích xxxxx.

X3. XXXXXX DOPING

Z xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx polymerů xxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxx;

2. Použití normálních xxxx geneticky modifikovaných xxxxx;

XXXXX A METODY XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 až X5 x X1 xx M3 xxxxxxxxx xxxx

xxxx Při Xxxxxxx xxxxxxxx x následující xxxxxxx:

XXXXXXXX LÁTKY

S6. STIMULANCIA

Všechna xxxxxxxxxxx xxxxxx všech xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. x- x X-, jsou xxxxxxxx.

Xxxxxxxxxxx zahrnují:

(a) Nespecifická xxxxxxxxxxx:

Xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/,

xxxxxxxxxx,

xxxxxxxxxxx,

xxxxxx,

xxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxx (x-),

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxxx, 

x-xxxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx není xxxxxxxx uvedeno v xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Specifická xxxxxxxxxxx.

Xxxxxxxx (ale xx x xxxxxxxx pouze xx xx):

Xxxxxxxxx (xxxxxxxxx)****,

xxxxxxxxxxx,

xxxxxxxxxxxxxxxxx,

xxxxxxx***,

xxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx x xxxx xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxx,

xxxxx**,

xxxxxxx a xxxx xxxxxxx (např. xxxxxxxx, xxxxxxxxx a xxxx-xxxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxxxx***,

xxxxxxxxxxxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx),

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxx (xxxxxxxxxxxxx),

xxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxxx,

xxxxxxxxxxxxx*****,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxxx

x xxxxx látky x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx imidazolu x případě xxxxxx xxxxxxxx/xxxxxx xxxxxxx a xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2017*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx x xxxxxxxx: Tyto látky xxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2017 x xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.

** Xxxxx: xx xxxxxxxx xxxxx xxx koncentraci xxxxx než 5 xxxxxxxxxx x 1 xx moči.

*** Xxxxxxx x methylefedrin: xxxx xxxxxxxx při xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx v 1 xx xxxx.

**** Xxxxxxxxx (xxxxxxxxx): xxxx zakázán xxx lokálním podání, xxxx. xxxxx, oční xxxxxxxx xxxx xxxx xxxxxx xxxxxxxx s xxxxxxxxx anestetiky.

***** Pseudoefedrin: xx zakázán, xxxxx xxxx xxxxxxxxxxx v xxxx xx xxxxx xxx 150 xxxxxxxxxx xx mililitr.

S7. XXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

Xxxxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx(xxxxxx),

xxxxxxxx x xxxx xxxxxxxx,

xxxxxxxxxxx,

xxxxxxx,

xxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxx.

X8. KANABINOIDY

Zakázané xx xxxxxxxxxxx:

• Xxxxxxxx (xxxx. xxxxx, konopí a xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (THC).

• Kanabimimetika, xxxx. "Xxxxx", XXX018, XXX073 x XX-210.

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx podávané xxxxxx, xxxxxxxx, nitrožilní xxxx xxxxxxxxxxxxx xxxxxxxx jsou xxxxxxxx.

XXXXX XXXXXXXX X&xxxx;XXXXXXXX XXXXXXXX

X1. XXXXXXX

Xxxxxxx (etanol) xx xxxxxxxx xxxxx Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxx 0,10 x/x.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxxxxx (XX)

• Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)

• Xxxxx xxxxxxxxxx (XXX)

X2. BETA-BLOKÁTORY

Beta-blokátory jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx sportech Při Xxxxxxx, a xxx xx xx označeno x Xxxx soutěž.

• Automobilový xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (FIS) - xxxxx xx xxxxxx x akrobatické xxxxxxxx-xxxxx x U-rampa, a xxxxxxxxx X-xxxxx x "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx xxxxxxxx) (XXXX) x xxxxxxxxxxxx xxxxxxxxxx xxxx x xxxxxxxxx xxxx xxx xxxxxxx, xxxxxxxxx apnoe x xxxxxxxxx xxxx xxx xxxxxxx, xxxx xxxxxxxxx, xxxx xxxx, spearfishing, xxxxxxxx apnoe, xxxxxxx xxxxxxxx na xxxx x xxxxxxxxxx váha.

• Střelba (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxx, 

xxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxx,

xxxxxxx,

xxx xx x xxxxxxxx pouze na xx.

Informace

Právní xxxxxxx x. 80/2017 Sb. x. x. nabyl xxxxxxxxx xxxx 4.1.2018.

Právní předpis x. 80/2017 Sb. x. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 36/2019 Sb. m. s. s xxxxxxxxx xx 26.7.2019.

Znění jednotlivých xxxxxxxx norem xxxxxx xxxxxxxx předpisů v xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx, xxxxxxx xxx 19. xxxxx 2005 x Paříži, xxxx xxxxxxxxx x xxxxxxxxx xxxxx x s xxxxxxxxx do xxxxxxx xxxxxx pod č. 58/2007 Sb. m. s.

Nové xxxxx překladu Xxxxxx xx xxxxxxx xxxxxx xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.